ARTICLE | Clinical News

Viread tenofovir disoproxil fumarate: Phase III preliminary data

September 6, 2004 7:00 AM UTC

A 24-week analysis of a 48-week, open-label European and U.S. Phase III trial (study 934) in 517 patients showed 88% of patients taking Viread 300 mg, Emtriva 200 mg and Sustiva 600 mg once-daily ma...